EP2488548A1 - Variant d'épissage de la protéine apparentée à la lipoprotéine de faible densité 1 en tant que marqueur du cancer - Google Patents

Variant d'épissage de la protéine apparentée à la lipoprotéine de faible densité 1 en tant que marqueur du cancer

Info

Publication number
EP2488548A1
EP2488548A1 EP10766044A EP10766044A EP2488548A1 EP 2488548 A1 EP2488548 A1 EP 2488548A1 EP 10766044 A EP10766044 A EP 10766044A EP 10766044 A EP10766044 A EP 10766044A EP 2488548 A1 EP2488548 A1 EP 2488548A1
Authority
EP
European Patent Office
Prior art keywords
seq
polypeptide
sequence
cancer
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10766044A
Other languages
German (de)
English (en)
Inventor
Wilhelm Gerdes
Monika Birkenmeier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomac Privatinstitut fur Medizinische und Zahnmedizinische Forschung Entwicklung und Diagnostik GmbH
Fraunhofer Gesellschaft zur Forderung der Angewandten Forschung eV
Original Assignee
Biomac Privatinstitut fur Medizinische und Zahnmedizinische Forschung Entwicklung und Diagnostik GmbH
Fraunhofer Gesellschaft zur Forderung der Angewandten Forschung eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomac Privatinstitut fur Medizinische und Zahnmedizinische Forschung Entwicklung und Diagnostik GmbH, Fraunhofer Gesellschaft zur Forderung der Angewandten Forschung eV filed Critical Biomac Privatinstitut fur Medizinische und Zahnmedizinische Forschung Entwicklung und Diagnostik GmbH
Priority to EP10766044A priority Critical patent/EP2488548A1/fr
Publication of EP2488548A1 publication Critical patent/EP2488548A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Abstract

La présente invention porte sur une molécule d'acide nucléique comprenant un exon alternatif de la protéine apparentée à la lipoprotéine de faible densité 1 (LRP1), sur une protéine codée par ladite molécule d'acide nucléique et sur des fragments dudit acide nucléique et de ladite protéine. La présente invention porte également sur des vecteurs, des cellules hôtes, des méthodes recombinantes pour la production de ladite protéine, des anticorps, des cellules de production d'anticorps, des ligands d'affinité et des antagonistes dudit acide nucléique et de la protéine et sur l'utilisation du variant d'épissage de LRP1 comme marqueur du cancer. L'invention porte également sur des compositions correspondantes de diagnostic et pharmaceutiques, des coffrets, des utilisations médicales et des procédés, ainsi que des vaccins et des procédés d'induction de réponses immunitaires.
EP10766044A 2009-10-14 2010-10-14 Variant d'épissage de la protéine apparentée à la lipoprotéine de faible densité 1 en tant que marqueur du cancer Withdrawn EP2488548A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10766044A EP2488548A1 (fr) 2009-10-14 2010-10-14 Variant d'épissage de la protéine apparentée à la lipoprotéine de faible densité 1 en tant que marqueur du cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09173001 2009-10-14
EP10766044A EP2488548A1 (fr) 2009-10-14 2010-10-14 Variant d'épissage de la protéine apparentée à la lipoprotéine de faible densité 1 en tant que marqueur du cancer
PCT/EP2010/065417 WO2011054644A1 (fr) 2009-10-14 2010-10-14 Variant d'épissage de la protéine apparentée à la lipoprotéine de faible densité 1 en tant que marqueur du cancer

Publications (1)

Publication Number Publication Date
EP2488548A1 true EP2488548A1 (fr) 2012-08-22

Family

ID=43085853

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10766044A Withdrawn EP2488548A1 (fr) 2009-10-14 2010-10-14 Variant d'épissage de la protéine apparentée à la lipoprotéine de faible densité 1 en tant que marqueur du cancer

Country Status (2)

Country Link
EP (1) EP2488548A1 (fr)
WO (1) WO2011054644A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011115480A1 (de) * 2011-10-06 2013-04-11 Biostep Gmbh Substrat und Vorrichtung zur Chemilumineszenzdetektion
EA033325B1 (ru) 2014-10-27 2019-09-30 Тэнша Терапеутикс, Инк. Ингибиторы бромодомена
WO2017200263A1 (fr) * 2016-05-17 2017-11-23 울산대학교 산학협력단 Composition de biomarqueur comprenant lrp-1 en tant que principe actif pour le diagnostic du cancer résistant à l'irradiation ou la prédiction du pronostic d'une radiothérapie
KR101952649B1 (ko) * 2016-05-17 2019-02-27 울산대학교 산학협력단 Lrp-1을 유효성분으로 포함하는 방사선 저항성 암 진단용 또는 방사선 치료 예후 예측용 바이오마커 조성물
US11466080B2 (en) 2017-03-22 2022-10-11 Children's Medical Center Corporation Methods of treating cancer using anti-LRP1 polyclonal antibodies
WO2018175765A1 (fr) * 2017-03-22 2018-09-27 Children's Medical Center Corporation Inhibition de prss2

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1991010741A1 (fr) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation d'anticorps xenogeniques
CA2110799A1 (fr) 1991-06-14 1992-12-23 Arnold H. Horwitz Fragments d'anticorps d'origine microbienne, et conjugues
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
AU693023B2 (en) 1995-05-05 1998-06-18 Applied Biosystems, Llc Methods and reagents for combined PCR amplification and hybridization probing assay
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
AU2006304605A1 (en) * 2005-10-17 2007-04-26 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
WO2009026116A2 (fr) * 2007-08-16 2009-02-26 Genizon Biosciences, Inc. Cartographie génétique des gènes humains associés à la longévité
EP2045266A1 (fr) * 2007-10-02 2009-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés pour le traitement et le diagnostic d'un cancer secrétant du cath-D ou la maladie d'Alzheimer

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 1 February 2003 (2003-02-01), "Homo sapiens low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor), mRNA (cDNA clone IMAGE:4859182), complete cds.", retrieved from EBI accession no. EM_HUM:BC045107 Database accession no. BC045107 *
DATABASE EMBL [online] 13 February 2010 (2010-02-13), "Transcriptome Microarray Technology and Methods of Using the Same.", retrieved from EBI accession no. EM_PAT:FU311672 Database accession no. FU311672 *
DATABASE EMBL [online] 21 May 2003 (2003-05-21), "Homo sapiens low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor), mRNA (cDNA clone IMAGE:6575284), complete cds.", retrieved from EBI accession no. EM_HUM:BC052593 Database accession no. BC052593 *
DATABASE EMBL [online] 27 March 2002 (2002-03-27), "UI-H-ED0-awx-i-02-0-UI.s1 NCI_CGAP_ED0 Homo sapiens cDNA clone IMAGE:5824969 3', mRNA sequence.", retrieved from EBI accession no. EM_EST:BM996932 Database accession no. BM996932 *
DATABASE EMBL [online] 3 June 2004 (2004-06-03), "Homo sapiens low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor), mRNA (cDNA clone IMAGE:6384902), complete cds.", retrieved from EBI accession no. EM_HUM:BC072015 Database accession no. BC072015 *
DATABASE GENESEQ [online] 24 January 2008 (2008-01-24), "Human tissue-derived serum glycoprotein SEQ ID NO:8721.", retrieved from EBI accession no. GSP:AJL93066 Database accession no. AJL93066 *
See also references of WO2011054644A1 *

Also Published As

Publication number Publication date
WO2011054644A1 (fr) 2011-05-12

Similar Documents

Publication Publication Date Title
US10927169B2 (en) Treatment of fibrosis with Interleukin-11 receptor alpha antibody
EP1203239B1 (fr) Utilisation d'un polypeptique pour detecter un etat pathologique associe a la sclerose en plaques
JP6381519B2 (ja) がん転移の予後診断および処置のための方法
US20210189342A1 (en) Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof
ES2397441T3 (es) Secuencias polinucleotídicas y polipeptídicas implicadas en el proceso de remodelación ósea
JP2016102116A (ja) 診断および治療のための腫瘍関連抗原の同定
JP2001510987A (ja) 哺乳動物のＣＤ９７αサブユニットを含む炎症および脈管形成を阻害するための方法および組成物
EP2488548A1 (fr) Variant d'épissage de la protéine apparentée à la lipoprotéine de faible densité 1 en tant que marqueur du cancer
JP5756014B2 (ja) がんの診断および治療のためのｖｈｚ
US20060078913A1 (en) Compositions, splice variants and methods relating to cancer specific genes and proteins
US20050142572A1 (en) Compositions, splice variants and methods relating to lung specific nucleic acids and proteins
FR2841786A1 (fr) Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune
FR2841787A1 (fr) Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120508

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20140729

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20141209